These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24852726)

  • 1. Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).
    Sánchez-Regaña M; Aldunce Soto MJ; Belinchón Romero I; Ribera Pibernat M; Lafuente-Urrez RF; Carrascosa Carrillo JM; Ferrándiz Foraster C; Puig Sanz L; Daudén Tello E; Vidal Sarró D; Ruiz-Villaverde R; Fonseca Capdevila E; Rodríguez Cerdeira MC; Alsina Gibert MM; Herrera Acosta E; Marrón Moya SE;
    Actas Dermosifiliogr; 2014 Dec; 105(10):923-34. PubMed ID: 24852726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails.
    Handa S
    Indian J Dermatol Venereol Leprol; 2010; 76(6):634-44. PubMed ID: 21079306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problem sites: scalp, palm and sole, and nail.
    Larko O
    Dermatol Clin; 1995 Oct; 13(4):771-7. PubMed ID: 8785882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents in nail psoriasis: efficacy data and considerations.
    Kyriakou A; Patsatsi A; Sotiriadis D
    Expert Opin Biol Ther; 2013 Dec; 13(12):1707-14. PubMed ID: 24156504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.
    Wozel G
    Clin Dermatol; 2008; 26(5):448-59. PubMed ID: 18755363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Puig L; Carrascosa JM; Carretero G; de la Cueva P; Lafuente-Urrez RF; Belinchón I; Sánchez-Regaña M; García-Bustínduy M; Ribera M; Alsina M; Ferrándiz C; Fonseca E; García-Patos V; Herrera E; López-Estebaranz JL; Marrón SE; Moreno JC; Notario J; Rivera R; Rodriguez-Cerdeira C; Romero A; Ruiz-Villaverde R; Taberner R; Vidal D;
    Actas Dermosifiliogr; 2013 Oct; 104(8):694-709. PubMed ID: 24018211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psoriasis in special localizations].
    Schmieder A; Peitsch WK
    Hautarzt; 2016 Jun; 67(6):454-63. PubMed ID: 27215754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response of secukinumab in palmoplantar psoriasis.
    Rocamora V; Garcías-Ladaria J
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy in treating palmoplantar and scalp psoriasis: A systematic review and network meta-analysis.
    Zhang L; Su Y; Shucheng H; Wang L; Jiang X
    J Am Acad Dermatol; 2024 Mar; 90(3):646-648. PubMed ID: 37977294
    [No Abstract]   [Full Text] [Related]  

  • 11. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Apremilast in Psoriasis: A Delphi Study.
    Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
    Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Khobzey K; Liskova I; Szegedi A; Pavlovsky L; Lunder T; Kingo K; Miljković J; Péč J; Bohinc M; Hojnik M
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):11-14. PubMed ID: 28352929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriatic nail disease: quality of life and treatment.
    Gupta AK; Cooper EA
    J Cutan Med Surg; 2009; 13 Suppl 2():S102-6. PubMed ID: 19799826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
    J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.
    Merola JF; Qureshi A; Husni ME
    Dermatol Ther; 2018 May; 31(3):e12589. PubMed ID: 29512290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adalimumab in difficult-to-treat psoriasis.
    Lanna C; Zangrilli A; Bavetta M; Campione E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13374. PubMed ID: 32246516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.